

## The last rites for cystoscopy?

Poster Session 09

Friday, 24 March  
12:30 - 14:00

**Location:** Room Vienna, North Hall (Level 1)

**Chairs:** P. Black, Vancouver (CA)  
R.T. Bryan, Birmingham (GB)

### Aims and objectives of this session

To understand where TCC molecular diagnostics is heading. Ready for prime time or more hype than hope?

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

117

### Validation of a mRNA-based urine test for bladder cancer detection in patients with hematuria

**By:** Van Valenberg F.J.P.<sup>1</sup>, Bridge J.A.<sup>2</sup>, Mayne D.<sup>3</sup>, Beqaj S.<sup>4</sup>, Sexton W.J.<sup>5</sup>, Lotan Y.<sup>6</sup>, Weizer A.Z.<sup>7</sup>, Jansz G.K.<sup>8</sup>, Stenzl A.<sup>9</sup>, Danella J.F.<sup>10</sup>, Shepard B.R.<sup>11</sup>, Cline K.J.<sup>12</sup>, Williams M.B.<sup>13</sup>, Montgomery T.<sup>14</sup>, David R.D.<sup>15</sup>, Harris R.G.<sup>16</sup>, Klein E.W.<sup>17</sup>, Bradford T.J.<sup>18</sup>, Wolk F.N.<sup>19</sup>, Westenfelder K.R.<sup>20</sup>, Trainer A.F.<sup>21</sup>, Richardson T.A.<sup>22</sup>, Witjes J.A.<sup>1</sup>

**Institutes:**<sup>1</sup>Radboudumc, Dept. of Urology, Nijmegen, The Netherlands, <sup>2</sup>University of Nebraska Medical Center, Departments of Pathology/Microbiology, Pediatrics and Orthopaedic Surgery, Omaha, United States of America, <sup>3</sup>Sacred Heart Hospital, Molecular Laboratory, Pensacola, United States of America, <sup>4</sup>Pathology Inc., Clinical Laboratory, Torrance, United States of America, <sup>5</sup>Moffitt Cancer Center, Genitourinary Oncology and Oncologic Sciences, Tampa, United States of America, <sup>6</sup>University of Texas Southwestern, Dept. of Urology, Dallas, United States of America, <sup>7</sup>University of Michigan Hospital, Dept. of Urology, Ann Arbor, United States of America, <sup>8</sup>G. Kenneth Jansz MPC, Private Practice, Burlington, Canada, <sup>9</sup>University of Tübingen, Dept. of Urology, Tübingen, Germany, <sup>10</sup>Geisinger Health System, Dept. of Urology, Danville, United States of America, <sup>11</sup>Urological Surgeons of Long Island, PLLC, Private Practice, Garden City, United States of America, <sup>12</sup>Regional Urology, Private Practice, Shreveport, United States of America, <sup>13</sup>Urology of Virginia, Private Practice, Virginia Beach, United States of America, <sup>14</sup>Kansas City Urology Care, Private Practice, Overland Park, United States of America, <sup>15</sup>Skyline Urology, Private Practice, Torrance, United States of America, <sup>16</sup>UroPartners, Private Practice, Melrose Park, United States of America, <sup>17</sup>Idaho Urologic Institute, Private Practice, Meridian, United States of America, <sup>18</sup>Virginia Urology, Private Practice, Richmond, United States of America, <sup>19</sup>Skyline Urology, Private Practice, Sherman Oaks, United States of America, <sup>20</sup>Five Valleys Urology, Private Practice, Missoula, United States of America, <sup>21</sup>Adult and Pediatric Urology & Urogynecology, Private Practice, Omaha, United States of America, <sup>22</sup>Wichita Urology Group, Private Practice, Wichita, United States of America

118

### Does smoking influence the performance of urine markers in the diagnosis of urothelial carcinoma?

**By:** Schnürer S., Hennenlotter J., Dockter K., Rausch S., Stenzl A., Todenhöfer T.

**Institutes:** Eberhard-Karls-University, Dept. of Urology, Tübingen, Germany

119

### Performance characteristics of a mRNA-based urine test for the detection of bladder cancer recurrence

**By:** Van Valenberg F.J.P.<sup>1</sup>, Bridge J.A.<sup>2</sup>, Mayne D.<sup>4</sup>, Beqaj S.<sup>5</sup>, Sexton W.J.<sup>6</sup>, Lotan Y.<sup>7</sup>, Weizer A.Z.<sup>8</sup>, Jansz G.K.<sup>9</sup>, Stenzl A.<sup>10</sup>, Danella J.F.<sup>3</sup>, Shepard B.R.<sup>11</sup>, Cline K.J.<sup>12</sup>, Williams M.B.<sup>13</sup>, Montgomery T.<sup>14</sup>, David R.D.<sup>15</sup>, Harris R.G.<sup>16</sup>, Klein E.W.<sup>17</sup>, Bradford T.J.<sup>18</sup>, Wolk F.N.<sup>19</sup>, Westenfelder K.R.<sup>20</sup>, Trainer A.F.<sup>21</sup>, Richardson T.A.<sup>22</sup>, Witjes J.A.<sup>1</sup>

**Institutes:**<sup>1</sup>Radboudumc, Dept. of Urology, Nijmegen, The Netherlands, <sup>2</sup>University of Nebraska Medical Center, Dept. of Pathology/Microbiolog, Pediatrics and Orthopaedic Surgery, Omaha, United States of America, <sup>3</sup>Geisinger Health System, Dept. of Urology, Danville, United States of

America, <sup>4</sup>Sacred Heart Hospital, Molecular Laboratory, Pensacola, United States of America, <sup>5</sup> Pathology Inc., Clinical Laboratory, Torrance, United States of America, <sup>6</sup>Moffitt Cancer Center, Genitourinary Oncology and Oncologic Sciences, Tampa, United States of America, <sup>7</sup>University of Texas Southwestern, Dept. of Urology, Dallas, United States of America, <sup>8</sup>University of Michigan Hospital, Dept. of Urology, Ann Arbor, United States of America, <sup>9</sup>G. Kenneth Jansz MPC, , Burlington, Canada, <sup>10</sup>University of Tübingen, Dept. of Urology, Tübingen, Germany, <sup>11</sup>Urological Surgeons of Long Island, PLLC, , Garden City, United States of America, <sup>12</sup>Regional Urology, , Shreveport, United States of America, <sup>13</sup>Urology of Virginia, , Virginia Beach, United States of America, <sup>14</sup>Kansas City Urology Care, Overland Park, United States of America, <sup>15</sup>Skyline Urology, , Torrance, United States of America, <sup>16</sup>UroPartners, , Melrose Park, United States of America, <sup>17</sup>Idaho Urologic Institute, , Meridian, United States of America, <sup>18</sup>Virginia Urology, , Richmond, United States of America, <sup>19</sup>Skyline Urology, , Sherman Oaks, United States of America, <sup>20</sup>Five Valleys Urology, , Missoula, United States of America, <sup>21</sup>Adult and Pediatric Urology & Urogynecology, , Omaha, United States of America, <sup>22</sup>Wichita Urology Group, , Wichita, United States of America

- 120 **Non invasive prediction of recurrences in bladder cancer by detecting TERT promoter mutations in urine**  
**By:** [Kara N.](#)<sup>1</sup>, Descotes F.<sup>2</sup>, Decaussin Petrucci M.<sup>2</sup>, Piaton E.<sup>2</sup>, Geiguer F.<sup>2</sup>, Rodriguez-Lafrasse C.<sup>2</sup>, Terrier J.E.<sup>1</sup>, Lopez J.<sup>2</sup>, Ruffion A.<sup>1</sup>  
**Institutes:**<sup>1</sup>Centre Hospitalier Lyon-Sud, Dept. of Urology, Pierre-Bénite, France, <sup>2</sup>Centre Hospitalier Lyon-Sud, Dept. of Molecular Biology and Biochemistry, Pierre-Bénite, France
- 121 **Multiplex proximity extension assay of 425 candidate biomarkers in the sera of bladder cancer patients: Correlation with stage and outcome**  
**By:** [Ward D.](#)<sup>1</sup>, Gordon N.<sup>1</sup>, Abbotts B.<sup>2</sup>, James N.<sup>3</sup>, Zeegers M.<sup>4</sup>, Cheng K.K.<sup>5</sup>, Bryan R.<sup>1</sup>  
**Institutes:**<sup>1</sup>University of Birmingham, Institute of Cancer and Genomic Sciences, Birmingham, United Kingdom, <sup>2</sup>University of Birmingham, Institute of Cancer and Genomic Sciences, Birmingham, United Kingdom, <sup>3</sup>University of Warwick, Clinical Trials Unit, Warwick, United Kingdom, <sup>4</sup>University of Maastricht, Dept. of Complex Genetics, Birmingham, United Kingdom, <sup>5</sup>University of Birmingham, School of Health and Population Sciences, Birmingham, United Kingdom
- 122 **Non-invasive diagnosis and monitoring of bladder cancer utilizing high-throughput genome sequencing on urine sediment**  
**By:** [Liu H.](#), Lin T., He W., Wang B., Xu K., Han J., Zheng J., Huang J.  
**Institutes:**Sun Yat-Sen Memorial Hospital, Dept. of Urology, Guangzhou, China
- 123 **Method of detecting bladder cancer by optical analysis of bodily fluids**  
**By:** [Rabah D.](#)  
**Institutes:**College of Medicine, King Saud University, Dept. of Surgery, Riyadh, Saudi Arabia
- 124 **Urethral wash cytology accuracy in the diagnosis of asymptomatic urethral recurrence after radical cystectomy for urothelial bladder cancer**  
**By:** Manica M.<sup>1</sup>, Naspro R.<sup>1</sup>, [Pellucchi F.](#)<sup>1</sup>, Rocchini L.<sup>1</sup>, Roscigno M.<sup>1</sup>, Chinaglia D.<sup>2</sup>, Da Pozzo L.F.<sup>1</sup>  
**Institutes:**<sup>1</sup>Papa Giovanni Xxiii Hospital, Dept. of Urology, Bergamo, Italy, <sup>2</sup>Papa Giovanni Xxiii Hospital, Dept. of Pathology, Bergamo, Italy
- 125 **Diagnosis and prediction of recurrent bladder cancer by urinary DNA methylation analysis: Multicenter prospective study**  
**By:** [Shindo T.](#)<sup>1</sup>, Shimizu T.<sup>1</sup>, Nishiyama N.<sup>1</sup>, Niinuma T.<sup>2</sup>, Kitajima H.<sup>2</sup>, Kai M.<sup>2</sup>, Shinkai N.<sup>1</sup>, Itoh N.<sup>3</sup>, Tanaka T.<sup>1</sup>, Suzuki H.<sup>2</sup>, Masumori N.<sup>1</sup>  
**Institutes:**<sup>1</sup>Sapporo Medical University School of Medicine, Dept. of Urology, Sapporo, Japan, <sup>2</sup>Sapporo Medical University School of Medicine, Dept. of Molecular Biology, Sapporo, Japan, <sup>3</sup>NTT East Corporation Sapporo Hospital, Dept. of Urology, Sapporo, Japan
- 126 **Urine-based diagnostics of bladder tumours through volatile organic compounds: A pilot study comparing two detection systems**

**By:** Heers H.<sup>1</sup>, Gut J.<sup>1</sup>, Hegele A.<sup>1</sup>, Hofmann R.<sup>1</sup>, Boeselt T.<sup>2</sup>, Hattesoehl A.<sup>2</sup>, Baumbach J.<sup>3</sup>, Koczulla A.R.<sup>2</sup>

**Institutes:**<sup>1</sup>Philipps-Universität Marburg, Dept. of Urology and Paediatric Urology, Marburg, Germany, <sup>2</sup>Philipps-Universität Marburg, Dept. of Pneumology, Marburg, Germany, <sup>3</sup>Reutlingen University, Dept. of Applied Chemistry, Reutlingen, Germany

127

**Effect of contemporary health screening not focused on bladder cancer on diagnosis of bladder urothelial carcinoma**

**By:** Suh Y.S., Sung H.H., Jeon H.G., Jeong B.C., Seo S.I., Lee H.M., Choi H.Y., Jeong J., Lee C.U., Jeon S.S.

**Institutes:**Samsung Medical Center, Sungkyunkwan University School of Medicine, Dept. of Urology, Seoul, South Korea

128

**Molecular tumour grading and classification of non muscle invasive bladder cancer based on whole transcriptome analysis**

**By:** Zlotta A.R.<sup>1</sup>, Shen J.<sup>2</sup>, Noon A.<sup>3</sup>, Jiang H.<sup>4</sup>, Kuk C.<sup>1</sup>, Ni R.<sup>5</sup>, Sukhu B.<sup>5</sup>, Chan K.<sup>2</sup>, Erlich A.<sup>1</sup>, Roupret M.<sup>6</sup>, Seisen T.<sup>6</sup>, Comparat E.<sup>7</sup>, Sweet J.<sup>8</sup>, Kulkarni G.S.<sup>9</sup>, Fleshner N.E.<sup>9</sup>, Azad A.<sup>5</sup>, Van Der Kwast T.H.<sup>8</sup>, Wrana J.L.<sup>2</sup>

**Institutes:**<sup>1</sup>Mount Sinai Hospital, Dept. of Surgery (urology), Toronto, Canada, <sup>2</sup>Mount Sinai Hospital, Lunenfeld-Tanenbaum Research Institute, Toronto, Canada, <sup>3</sup>University of Sheffield, Dept. of Urology, Sheffield, United Kingdom, <sup>4</sup>University Health Network, Dept. of Statistics, Toronto, Canada, <sup>5</sup>Mount Sinai Hospital, Dept. of Pathology and Laboratory Medicine, Toronto, Canada, <sup>6</sup>Groupe Hospitalier La Pitié-Salpêtrière, Université Pierre Et Marie Curie, Dept. of Urology, Paris, France, <sup>7</sup>Groupe Hospitalier La Pitié-Salpêtrière, Université Pierre Et Marie Curie, Dept. of Pathology, Paris, France, <sup>8</sup>Toronto General Hospital, University Health Network, Dept. of Pathology, Toronto, Canada, <sup>9</sup>Princess Margaret Cancer Centre, University Health Network, Dept. of Surgical Oncology, Urology, Toronto, Canada

129

**Significance of serum n-glycan profiling as a diagnostic biomarker in urothelial carcinoma**

**By:** Oikawa M.<sup>1</sup>, Hatakeyama S.<sup>1</sup>, Yoneyma T.<sup>2</sup>, Tobisawa Y.<sup>1</sup>, Narita T.<sup>1</sup>, Yamamoto H.<sup>1</sup>, Hashimoto Y.<sup>2</sup>, Koie T.<sup>1</sup>, Narita S.<sup>3</sup>, Sasaki A.<sup>4</sup>, Tsuchiya N.<sup>5</sup>, Habuchi T.<sup>3</sup>, Takahashi I.<sup>6</sup>, Nakaji S.<sup>6</sup>, Ohyama C.<sup>1</sup>

**Institutes:**<sup>1</sup>Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, <sup>2</sup>Hirosaki University Graduate School of Medicine, Dept. of Advanced Transplant and Regenerative Medicine, Hirosaki, Japan, <sup>3</sup>Akita University Graduate School of Medicine, Dept. of Urology, Akita, Japan, <sup>4</sup>Tsugaru General Hospital, Dept. of Urology, Tsugaru, Japan, <sup>5</sup>Yamagata University Graduate School of Medicine, Dept. of Urology, Yamagata, Japan, <sup>6</sup>Hirosaki University School of Medicine, Dept. of Social Medicine, Hirosaki, Japan

130

**Concurrent bladder tumours in patients undergoing photodynamic diagnostic ureterorenoscopy: How many lesions are missed under white light?**

**By:** Zreik A.<sup>1</sup>, Kata S.G.<sup>2</sup>, Ahmad S.<sup>2</sup>, Chlosta P.L.<sup>3</sup>, Aboumarzouk O.M.<sup>1</sup>

**Institutes:**<sup>1</sup>Queen Elizabeth University Hospital, Dept. of Urology, Glasgow, United Kingdom, <sup>2</sup>Ninewells Hospital, Dept. of Urology, Dundee, United Kingdom, <sup>3</sup>Jagiellonian University, Dept. of Urology, Cracow, Poland

13:49 - 13:56

**Last word on the last rite**

P. Black, Vancouver (CA)